Galena Biopharma (GALE) Reports Q4 Loss of $0.17/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Galena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update
March 15, 2017 4:15 PM EDTSAN RAMON, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today reported its financial results for the quarter and year ended December 31, 2016.
I am honored to be selected by the Board of Directors to lead Galena as we explore the best possible outcome for the company and its shareholders, said Stephen F. Ghiglieri, Interim Chief Executive Officer. As we announced last week, we are working closely with our advisors, Canaccord Genuity, Inc., to evaluate strategic alternatives that may... More
